Loading
Adebrelimab is Hengrui's PD-L1 antibody, approved in China for first-line extensive-stage small cell lung cancer on the CAPSTONE-1 trial.
CAPSTONE-1 randomised 462 patients with extensive-stage small cell lung cancer to adebrelimab or placebo with carboplatin and etoposide: median overall survival 15.3 versus 12.8 months (hazard ratio 0.72), among the largest survival gains reported for a PD-L1 antibody in this disease. The NMPA approved the combination in March 2023. Hengrui is testing adebrelimab in limited-stage disease after chemoradiotherapy and with its own ADCs.
Humanised anti-PD-L1 IgG4 antibody blocking PD-L1 binding to PD-1 and B7-1. Connects to PD-L1.
1.Adebrelimab binds PD-L1.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2023 | First-line extensive-stage small cell lung cancer with carboplatin and etoposide (CAPSTONE-1) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Adebrelimab" OR ABSTRACT:"Adebrelimab" OR TITLE:"Arelili" OR ABSTRACT:"Arelili" OR TITLE:"SHR-1316" OR ABSTRACT:"SHR-1316") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Adebrelimab, not a curated reading list.
Shares CD80 (B7-1), PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Monoclonal antibodies and the tag china.
Shares A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo, A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat and the tag china.
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Monoclonal antibodies, Immune checkpoint inhibitors and the tag china.
Shares Adebrelimab + Apatinib in SCLC Maintenance Therapy, Jiangsu Hengrui Pharmaceuticals and the tag china.
Shares Ying Cheng, Small-cell lung cancer and the tag china.
Shares A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors and the tag china.
Shares Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors and the tag china.
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, Monoclonal antibodies, Immune checkpoint inhibitors and the tag china.